Beyond antiangiogenesis: Intratumorally injected bevacizumab plays a cisplatin-sensitizing role in squamous cell carcinomas in mice

Chemotherapy

Volumn 57, Issue 3, 2011, Pages 244-252

  Wang, Yixiang ^a   Dong, Ling ^a   Bi, Qingwei ^b   Ge, Xiyuan ^a   Zhang, Xiaoxia ^a   Wu, Dengcheng ^a   Fu, Jia ^a   Zhang, Chengfei ^c   Wang, Cunyu ^d   Li, Shenglin ^a  

^a PEKING UNIVERSITY   (China)

^b Department of Oral Surgery   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d UCLA SCHOOL OF DENTISTRY   (United States)

Author keywords

Antiangiogenesis; Anticancer mechanism; Bevacizumab; Cisplatin; Squamous cell carcinoma

Indexed keywords

BEVACIZUMAB; CASPASE 3; CD34 ANTIGEN; CISPLATIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HELA CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MICROVASCULATURE; MONOTHERAPY; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION; SQUAMOUS CELL CARCINOMA; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CASPASE 3; CELL LINE, TUMOR; CISPLATIN; DISEASE MODELS, ANIMAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL RATE;

EID: 79955960642     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000326485     Document Type: Article

References (38)

1. Midgley R, Kerr D: Bevacizumab - current status and future directions. Ann Oncol 2005;16:999-1004. (Pubitemid 41418303)
2. Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D: Vascular endo-thelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 2006;13:1845-1857.
3. Two new drugs for colon cancer. Med Lett Drugs Ther 2004;46:46-48.
4. Scott LJ: Bevacizumab: in first-line treatment of metastatic breast cancer. Drugs 2007;67:1793-1799. (Pubitemid 47263182)
5. Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF, Panageas KS, Boyd J, Yeh B, Lake DE, Dang CT, Gilewski TA, Bromberg JF, Seidman AD, D'Andrea GM, Moasser MM, Melisko M, Park JW, Dancey J, Norton L, Hudis CA: A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin Cancer Res 2008;14:7878-7883.
6. Riely GJ, Rizvi NA, Kris MG, Milton DT, Solit DB, Rosen N, Senturk E, Azzoli CG, Brahmer JR, Sirotnak FM, Seshan VE, Fogle M, Ginsberg M, Miller VA, Rudin CM: Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. J Clin Oncol 2009;27:264-270.
7. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ: Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26:5422-5428.
8. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N, AVOREN Trial investigators: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103-2111. (Pubitemid 350296300)
9. Mabuchi S, Terai Y, Morishige K, Tanabe-Kimura A, Sasaki H, Kanemura M, Tsunetoh S, Tanaka Y, Sakata M, Burger RA, Kimura T, Ohmichi M: Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model. Clin Cancer Res 2008;14:7781-7789.
10. Marshall J: The role of bevacizumab as firstline therapy for colon cancer. Semin Oncol 2005;32:S43-S47. (Pubitemid 43080915)
11. Lilenbaum R, Raez L, Tseng J, Seigel L, Davila E: Efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in advanced non-small cell lung cancer. J Thorac Oncol 2008;3:511-515. (Pubitemid 351630279)
12. Corvo R: Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiother Oncol 2007;85:156-170. (Pubitemid 47562578)
13. Mandpe AH, Tsung K, Norton JA: Cure of an established nonimmunogenic tumor, SCC VII, with a novel interleukin 12-based im-munotherapy regimen in C3H mice. Arch Otolaryngol Head Neck Surg 2003;129:786-792. (Pubitemid 36858969)
14. O'Malley BW Jr, Cope KA, Johnson CS, Schwartz MR: A new immunocompetent murine model for oral cancer. Arch Otolaryngol Head Neck Surg 1997;123:20-24. (Pubitemid 27043653)
15. Khurana D, Martin EA, Kasperbauer JL, O'Malley BW Jr, Salomao DR, Chen L, Strome SE: Characterization of a spontaneously arising murine squamous cell carcinoma (SCC VII) as a prerequisite for head and neck cancer immunotherapy. Head Neck 2001;23:899-906. (Pubitemid 32862295)
16. Adelstein DJ, Rodriguez CP: Current and emerging standards of concomitant chemo-radiotherapy. Semin Oncol 2008;35:211-220. (Pubitemid 351787694)
17. Salama JK, Vokes EE: Concurrent chemotherapy and re-irradiation for locoregionally recurrent head and neck cancer. Semin Oncol 2008;35:251-261. (Pubitemid 351787700)
18. Wang Y, Bi Q, Dong L, Li X, Ge X, Zhang X, Fu J, Wu D, Li S: Quinacrine enhances cis-platin-induced cytotoxicity in four cancer cell lines. Chemotherapy 2010;56:127-134.
19. Xie X, Yang D, Ye Z, Tao H: Enhancement effect of adenovirus-mediated antisense c-myc and caffeine on the cytotoxicity of cis-platin in osteosarcoma cell lines. Chemotherapy 2009;55:433-440.
20. Öksüzoglu B, Abali H, Hayran M, Yildirim N, Budakoglu B, Zengin N: C apecitabine and cisplatin combination is an active and well-tolerated doublet in the treatment of meta-static breast carcinoma patients pretreated with anthracycline and taxanes. Chemotherapy 2008;54:352-356.
21. Tufekci O, Gunes D, Ozoǧul C, Kolatan E, Altun Z, Yilmaz O, Aktaş S, Erbayraktar Z, Kirkim G, Mutafoǧlu K, Soylu A, Serbetçioǧlu B, Güneri EA, Olgun N: Evaluation of the effect of acetyl L-carnitine on experimental cisplatin nephrotoxicity. Chemotherapy 2009;55:451-459.
22. Saleh S, Ain-Shoka AA, El-Demerdash E, Khalef MM: Protective effects of the angio-tensin II receptor blocker losartan on cis-platin-induced kidney injury. Chemotherapy 2009;55:399-406.
23. Gallagher R, Hughes CM, Murray MM, Friery OP, Patterson LH, Hirst DG, McKeown SR: The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N. Br J Cancer 2001;85:625-629. (Pubitemid 32808290)
24. Sandler A: Bevacizumab in non-small cell lung ca ncer. Clin Cancer Res 2007;13:s4613-s4616.
25. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG: Side popu lat ion is enriched in tumorigenic, stemlike cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumori-genic. Cancer Res 2005;65:6207-6219. (Pubitemid 40994406)
26. Hansen S, Grabau DA, Sorensen FB, Bak M, Vach W, Rose C: The prognostic value of an-giogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients. Clin Cancer Res 2000;139:139-146. (Pubitemid 30064986)
27. de Jong JS, van Diest PJ, Baak JP: Hot spot microvessel density and the mitotic activity index are strong additional prognostic indicators in invasive breast cancer. Histopathology 2000;36:306-312. (Pubitemid 30198912)
28. Inoue K, Slaton JW, Perrotte P, Davis DW, Bruns CJ, Hicklin DJ, McConkey DJ, Sweeney P, Radinsky R, Dinney CP: Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 2000;6:4874-4884. (Pubitemid 32110432)
29. Cancer Facts & figures 2008. Atlanta, American Cancer Society, 2008, p15-16.
30. Ziober BL, Mauk MG, Falls EM, Chen Z, Ziober AF, Bau HH: Lab-on-a-chip for oral cancer screening and diagnosis. Head Neck 2008;30:111-121. (Pubitemid 351158328)
31. Xu ZQ, Liu Y, Wang YX, Zhang W, Zhao FY: Therapeutic effects of Avastin on murine hemangioendothelioma. Beijing Da Xue Xue Bao 2009;41:105-108.
32. de Gramont A, Van Cutsem E: Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology 2005;69:46-56. (Pubitemid 41680952)
33. Bozec A, Sudaka A, Fischel JL, Brunstein MC, Etienne-Grimaldi MC, Milano G: Combined effects of bevacizumab with erlo-tinib and irradiation: a preclinical study on a head and neck cancer orthotopic model. Br J Cancer 2008;99:93-99. (Pubitemid 351920227)
34. Hung H: Bevacizumab plus 5-fluorouracil induce growth suppression in the CWR-22 and CWR-22R prostate cancer xenografts. Mol Cancer Ther 2007;6:2149-2157. (Pubitemid 47294743)
35. Petros AM, Olejniczak ET, Fesik SW: Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta 2004;1644:83-94. (Pubitemid 38281265)
36. Adams JM, Cory S: Bcl-2-regulated apopto-sis: mechanism and therapeutic potential. Curr Opin Immunol 2007;19:488-496. (Pubitemid 47487452)
37. Garrido C, Galluzzi L, Brunet M, Puig PE, Didelot C, Kroemer G: Mechanisms of cyto-chromec release from mitochondria. Cell Death Differ 2006;13:1423-1433.
38. McFarland DC, Pesall JE: Phospho-MAPK as a marker of myogenic satellite cell responsiveness to growth factors. Comp Biochem Physiol B Biochem Mol Biol 2008;149:463-467.